Fresh from a US court refusing to grant Roche’s Genentech a temporary injunction pending appeal of a comprehensive non-infringement ruling, Sandoz has launched at-risk the first US generic version of the originator’s Esbriet (pirfenidone) film-coated tablets to treat idiopathic pulmonary fibrosis.
Bolstering Sandoz’s respiratory portfolio, the launch also brings generic competition to one of only two drugs approved by the US Food and Drug Administration for IBF – and one that